Tech Company Financing Transactions

Audentes Therapeutics Funding Round

Audentes Therapeutics, based in San Francisco, secured $30 million from OrbiMed, 5AM Ventures and Versant Ventures.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A

OrbiMed (Lead Investor) (Jonathan Silverstein)

5AM Ventures (Kush Parmar)

Versant Ventures (Thomas Woiwode)

Proceeds Purpose
This funding will allow the Company to further advance its two lead programs, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs.

Company Information

Company Status
Mailing Address
600 California St. 17th Floor
San Francisco, CA 94108
Email Address
Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.
Audentes Therapeutics LinkedIn Company Profile
Social Media
Audentes Therapeutics Company Twitter Account
Company News
Audentes Therapeutics News
Audentes Therapeutics on Facebook
Audentes Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Matthew Patterson
  Matthew Patterson LinkedIn Profile  Matthew Patterson Twitter Account  Matthew Patterson News  Matthew Patterson on Facebook
Chief Financial Officer
Thomas Soloway
  Thomas Soloway LinkedIn Profile  Thomas Soloway Twitter Account  Thomas Soloway News  Thomas Soloway on Facebook
Chief Operating Officer
Natalie Holles
  Natalie Holles LinkedIn Profile  Natalie Holles Twitter Account  Natalie Holles News  Natalie Holles on Facebook
Vice President
Fulvio Mavilio
  Fulvio Mavilio LinkedIn Profile  Fulvio Mavilio Twitter Account  Fulvio Mavilio News  Fulvio Mavilio on Facebook
VP - Regulatory Affairs
Mary Newman
  Mary Newman LinkedIn Profile  Mary Newman Twitter Account  Mary Newman News  Mary Newman on Facebook



Browse more venture capital transactions:

Prev: 7/19/2013: mxHero venture capital transaction
Next: 7/19/2013: Lytics venture capital transaction


Share this article


News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary